Circulating pre-diagnostic metabolites and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a population-based study of 12 cohorts

Clicks: 1
ID: 320392
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #319 of 332 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 332 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Underlying metabolic perturbations may offer insight into etiological factors related to liver cancer development. The objective of this study was to explore associations between pre-diagnostic metabolites and risk of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Methods We conducted a nested case–control study within 12 prospective U.S. cohort studies, including 727 HCC cases and 126 ICC cases with matched controls. Metabolomic profiling was performed on pre-diagnostic blood samples using the Metabolon platform. Multivariable conditional logistic regression estimated adjusted odds ratios and 95% confidence intervals for associations between metabolites (per doubling in levels) and liver cancer risk. Elastic net regression selected metabolites predictive of HCC and ICC, with predictive performance assessed by area under the curve (AUC). Results Median time from blood collection to diagnosis was 11.6 years. Of 1,485 pre-diagnostic metabolites, 600 were associated with HCC risk after false discovery rate correction (366 positively, 234 negatively); no metabolites were significantly associated with ICC. Enriched pathways among HCC cases included methylhistidine metabolism, amino acid metabolism, and bile acid biosynthesis; ICC showed enrichment in valine, leucine, and isoleucine pathways. Elastic net models for HCC selected 38 metabolites with strong predictive performance (AUC = 0.87; 95% CI: 0.83 to 0.91), while eight metabolites were selected for ICC with modest discrimination (AUC = 0.64; 95% CI: 0.49 to 0.80). Conclusions Numerous pre-diagnostic metabolites were associated with HCC risk, potentially reflecting underlying liver dysfunction. Enrichment patterns suggest distinct metabolic perturbations between HCC and ICC. Larger studies are needed to characterize metabolic risk factors for ICC and evaluate metabolites as predictors of HCC risk.
Reference Key
openalex_W7167896820 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cody Z. Watling, Eleanor L. Watts, Erikka Loftfield, Barry I. Graubard, Hyokyoung G Hong, Xuehong Zhang, Matthew J Barnett, Julie E. Buring, Mollie E. Barnard, Yu Chen, A Heather Eliassen, J Michael Gaziano, Jonathan N Hofmann, Wen‐Yi Huang, Jae H Kang, Jill Koshiol, I‐Min Lee, Steven C Moore, Lorelei A. Mucci, Marian L Neuhouser, Christina C. Newton, Mark P. Purdue, Howard D Sesso, Martha Shrubsole, Rashmi Sinha, Lesley Tinker, Triplette Matthew, Caroline Y. Um, Kala Visvanathan, Jean Wactawski‐Wende, Walter C Willett, Fen Wu, Wei Zheng, Peter T. Campbell, DINESH BARUPAL, Jessica L. Petrick, Katherine A. McGlynn
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag227
URL
https://doi.org/10.1093/jnci/djag227
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.